Biomaterials Advances, Год журнала: 2024, Номер 168, С. 214121 - 214121
Опубликована: Ноя. 19, 2024
Язык: Английский
Biomaterials Advances, Год журнала: 2024, Номер 168, С. 214121 - 214121
Опубликована: Ноя. 19, 2024
Язык: Английский
Discover Nano, Год журнала: 2024, Номер 19(1)
Опубликована: Март 7, 2024
Abstract Breast cancer is a complex and heterogeneous disease, encompassing various subtypes characterized by distinct molecular features, clinical behaviors, treatment responses. Categorization of based on the presence or absence estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2), leading to such as luminal A, B, HER2-positive, triple-negative breast (TNBC). TNBC, comprising around 20% all cancers, lacks expression ER, PR, HER2 receptors, rendering it unresponsive targeted therapies presenting significant challenges in treatment. TNBC associated with aggressive behavior, high rates recurrence, resistance chemotherapy. Tumor initiation, progression, are attributed stem cells (BCSCs), which possess self-renewal, differentiation, tumorigenic potential. Surface markers, self-renewal pathways (Notch, Wnt, Hedgehog signaling), apoptotic protein (Bcl-2), angiogenesis inhibition (VEGF inhibitors), immune modulation (cytokines, checkpoint inhibitors) among key targets discussed this review. However, targeting BCSC subpopulation presents challenges, including off-target effects, low solubility, bioavailability anti-BCSC agents. Nanoparticle-based offer promising approach target cellular processes implicated survival BSCS TNBC. In review, we explore nanocarrier-based approaches for BCSCs aiming overcome these improve outcomes patients. These nanoparticle-based therapeutic strategies hold promise addressing gap delivering while minimizing systemic toxicity enhancing efficacy. Graphical abstract
Язык: Английский
Процитировано
20Coordination Chemistry Reviews, Год журнала: 2024, Номер 508, С. 215754 - 215754
Опубликована: Март 12, 2024
The science of nanotechnology has been proposed as a factor main change in the field cancer diagnosis and treatment. challenges common clinical treatment breast can be dominate by proof targeting cells nanoscale drug delivery system. Due to specific properties nanoparticles such biocompatibility, minimum toxicity, excellent stability, multifunctional encapsulations therapeutic agents, increased permeability retention effect, selective targeting, they apply for therapy. Multidrug resistance many chemotherapy drugs is one conventional that overcome nanoparticles. However, vivo vitro studies limited this field, number approved nano formulation not significantly over years. Successful translation nanomedicines arduous requiring considerable preclinical tests. Two-dimensional (2D) monolayer cell cultures animal models, which are routinely used research discovery/screening seem inadequate. To address challenge, biomimetic three-dimensional (3D) tumor models like spheroids, organoids, scaffolds/hydrogels, bioprinted, microfluidic chips have established using engineering approach. Taking physiopathology microenvironment into account, potential enhance disease modeling drug/nanomedicine screening. development 3D comprised patient's own cancer, stromal, immune exploited promising platform provide personalized
Язык: Английский
Процитировано
15Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер 100, С. 106007 - 106007
Опубликована: Авг. 5, 2024
Globally, cancer is regarded as a severe health issue. Among these breast (BC), the second most common kind in women after skin cancer. According to statistical data from NIH Cancer Institute, expected number of cases was around 3 lakh people, with 7.1 % fatality rate. The rise multidrug resistance (MDR) British Columbia issue it lowers effectiveness existing treatments. Traditional MDR treatment approaches BC have drawbacks, including toxicity, high cost, early discharge, restricted drug load before target, and poor effectiveness. Preventing has depended heavily on developing innovative therapy delivery methods utilizing nanomedicine new diagnosing treating BC. This review discusses its pathophysiology relation tumor kinetics. It focuses latest therapeutic over traditional like Surgery, Chemotherapy, Nanomedicine, Phototherapy, Immunotherapy, Gene therapy. also describes diagnostic techniques using MRI/PET, Mammography, Microwave Sensing, In-silico methods, Molecular techniques, AI-machine learning-based tools. discussed limitations nanoparticles article aims identify efficient ways diagnose treat prevent recurrence.
Язык: Английский
Процитировано
13Coordination Chemistry Reviews, Год журнала: 2024, Номер 508, С. 215796 - 215796
Опубликована: Март 17, 2024
Язык: Английский
Процитировано
10Journal of Drug Delivery Science and Technology, Год журнала: 2025, Номер unknown, С. 106620 - 106620
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
2Carbohydrate Polymers, Год журнала: 2024, Номер 330, С. 121818 - 121818
Опубликована: Янв. 15, 2024
Язык: Английский
Процитировано
6Heliyon, Год журнала: 2024, Номер 10(11), С. e31212 - e31212
Опубликована: Май 14, 2024
Functionalized graphene oxide nanoparticles (NPs) have emerged as promising nanocarriers for drug delivery in lung cancer therapy. Quercetin and lurbinectedin encapsulated (GO) NPs are tested treating A549 cells. Spectroscopic analyses show that functionalization creates a transparent, smooth surface loading.Treatment with quercetin/lurbinectedin-loaded GO induces notable cytotoxic effects cells, evidenced by distinct morphological alterations confirmed apoptotic cellular death observed through fluorescence microscopy. Additionally, our study highlights the impact of this approach on metastasis, supported qRT-PCR analysis relative gene expression levels, including p53, Bax, Caspase-3, Bcl2, revealing robust molecular mechanisms underlying therapeutic efficacy against PC9 cell lines. Flow cytometric further confirm induction cells following administration nanoformulation. Our findings may be treatment, opening new avenues targeted effective therapies.
Язык: Английский
Процитировано
6Drug Delivery and Translational Research, Год журнала: 2024, Номер unknown
Опубликована: Май 16, 2024
Язык: Английский
Процитировано
6International Journal of Pharmaceutics, Год журнала: 2024, Номер 660, С. 124346 - 124346
Опубликована: Июнь 16, 2024
Язык: Английский
Процитировано
4International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 139951 - 139951
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0